{"id":742068,"date":"2011-11-10T09:55:00","date_gmt":"2011-11-10T09:55:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/"},"modified":"2026-08-10T13:01:15","modified_gmt":"2026-08-10T17:01:15","slug":"merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/","title":{"rendered":"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing"},"content":{"rendered":"<p class=\"bwalignc\">       Plans eight U.S. filings in 2012-2013 and profiles innovative        candidates in Alzheimer&#8217;s disease, diabetes, hepatitis C and psoriasis     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE:MRK), known outside the United States and Canada as MSD,        today is hosting a R&amp;D and Business Briefing.     <\/p>\n<p>       &#8220;Innovation is the centerpiece of our growth strategy at Merck,&#8221; said        Kenneth C. Frazier, president and chief executive officer. &#8220;We continue        to make significant progress on our strategy to drive growth from our        existing portfolio and to bring forward breakthrough medicines and        vaccines that address unmet medical needs and return significant value        to our shareholders.&#8221;     <\/p>\n<p>       At the meeting, Peter S. Kim, president of Merck Research Laboratories,        four of the company&#8217;s therapeutic area research franchise heads, and the        president of Merck BioVentures provided an overview of candidates in        development and progress in advancing the company&#8217;s pipeline. Merck has        19 candidates in Phase III clinical trials targeting a broad range of        diseases. The company plans to submit eight new U.S. filings in        2012-2013, including five new candidates: TREDAPTIVE [ER        niacin\/laropiprant] (atherosclerosis), suvorexant (insomnia), odanacatib        (osteoporosis), V503 (cervical cancer vaccine) and BRIDION [sugammadex]        (reversal of neuromuscular blockade).     <\/p>\n<p>       &#8220;Merck&#8217;s strong late-stage pipeline has considerable potential,&#8221; said        Kim. &#8220;We continue to advance important, novel candidates both in our        late-stage pipeline and in our earlier pipeline to deliver on our goals        to provide patients with meaningful improvements over today&#8217;s treatments        and to help advance global health care.&#8221;     <\/p>\n<p>       In addition, the company highlighted six novel candidates in various        stages of development being evaluated for the treatment of        atherosclerosis (anacetrapib), type 2 diabetes (MK-3102), prevention of        herpes zoster (V212), psoriasis (MK-3222), hepatitis C infection        (MK-5172), Alzheimer&#8217;s disease (MK-8931), several of which have the        potential to transform medical care.     <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">         Anacetrapib is a novel reversible and selective cholesteryl ester          transfer protein (CETP) inhibitor being investigated in a large Phase          III outcomes study, the REVEAL study, for the treatment of          atherosclerosis. This candidate is anticipated to be filed after the          results of the study become available; results from REVEAL are          expected after 2015.       <\/li>\n<li class=\"bwlistitemmargb\">         MK-3102 is a novel, once-weekly oral dipeptidyl peptidase-4 (DPP-4)          inhibitor candidate for the treatment of type 2 diabetes. In research          presented, MK-3102 administered once-weekly showed greater than 80          percent inhibition of DPP-4 for seven days. MK-3102 is anticipated to          enter Phase III clinical trials in 2012.       <\/li>\n<li class=\"bwlistitemmargb\">         V212 is an inactivated varicella-zoster virus (VZV) vaccine in Phase          III development for the prevention of herpes zoster (shingles) in          immunocompromised individuals.       <\/li>\n<li class=\"bwlistitemmargb\">         MK-3222 is an anti-interleukin-23 (IL-23) monoclonal antibody          candidate being investigated for the treatment of psoriasis. MK-3222          is anticipated to enter Phase III clinical trials in 2012.       <\/li>\n<li class=\"bwlistitemmargb\">         MK-5172 is a potent, oral pan-genotypic NS3\/4a protease inhibitor.          Data from a study presented last week at the 2011 American Association          for the Study of Liver Diseases meeting showed MK-5172 suppressed HCV          in patients infected with HCV genotypes 1 and 3. In addition, new <i>in          vitro<\/i> data shows antiviral activity against a wide range of          resistant mutant HCV types. Phase II clinical trials evaluating          MK-5172 in combination with pegylated interferon\/ribavirin were          initiated earlier this year. The company is actively pursuing the use          of MK-5172 in an interferon-free regimen for HCV.       <\/li>\n<li class=\"bwlistitemmargb\">         MK-8931 is a novel, potentially first-in-class, potent \u03b2-site amyloid          precursor protein cleaving enzyme (BACE1) inhibitor being investigated          for the treatment of Alzheimer&#8217;s disease. Initiation of a Phase II          clinical trial is anticipated in 2012.       <\/li>\n<\/ul>\n<p>       Biosimilars continue<b> <\/b>to represent an important component of        Merck&#8217;s balanced pipeline portfolio. Merck BioVentures has established        strong development and manufacturing collaborations and continues to        make good progress in advancing its biosimilars portfolio. Merck will        strategically advance into Phase III for specific opportunities where        the company can be a first mover upon patent expiry of the originator        product.     <\/p>\n<p>       <b>Pipeline Progress Throughout Integration<\/b>     <\/p>\n<p>       Merck underscored the strong progress that the company has made in the        integration of the two legacy research organizations since the        completion of the merger on November 4, 2009. During the integration        period, the company continued to advance its strong pipeline of        candidates, with eight new molecular entity and combination products        receiving regulatory approval: BRINAVESS (vernakalant) (EU), DULERA<sup> <\/sup>(formoterol\/mometasone)        (U.S.), ELONVA<sup> <\/sup>(corifollitropin-\u03b1) (EU), JUVISYNC        (sitagliptin\/simvastatin) (U.S.), SYCREST (asenapine) (EU), VICTRELIS        (boceprevir) (EU &amp; U.S.), ZOELY (nomegestrol acetate\/ 17\u03b2-estradiol)        (EU) and CUBICIN (daptomycin for injection) (Japan).     <\/p>\n<p>       <b>Merck&#8217;s Strong Pipeline<\/b>     <\/p>\n<p>       Merck&#8217;s late-stage pipeline consists of 32 Phase II and Phase III        candidates including new molecular entities and combination programs.        Recent notable progress includes two cancer candidates, MK-1775 and        MK-2206 that have moved into Phase II trials. In addition, Phase III        studies have been initiated for MK-3415A, a candidate for the treatment        of <i>C. difficile<\/i> infection and MK-0431E, a novel investigational        combination of sitagliptin and atorvastatin being evaluated for the        treatment of type 2 diabetes and atherosclerosis.     <\/p>\n<p>       An interactive pipeline chart that lists investigational candidates in        Phase II and Phase III of clinical development as well as candidates        currently under regulatory review can be accessed at: <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fresearch%2Fpipeline%2Fhome.html&amp;esheet=50065498&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fresearch%2Fpipeline%2Fhome.html&amp;index=1&amp;md5=66578a90ae199e922f9a624e7b439195\">http:\/\/www.merck.com\/research\/pipeline\/home.html<\/a>.     <\/p>\n<p>       <b>Webcast information<\/b>     <\/p>\n<p>       The archived presentations from the R&amp;D and Business Briefing will be        available for viewing for 12 months following the event at <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Finvestors%2Fhome.html&amp;esheet=50065498&amp;lan=en-US&amp;anchor=www.merck.com%2Finvestors%2Fhome.html&amp;index=2&amp;md5=5dd00312c201ff360394961c93812aaa\">www.merck.com\/investors\/home.html<\/a>.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=50065498&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=3&amp;md5=b8a977f2cde6c0344d16ade9836fb90b\">www.merck.com<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the United States and internationally and the exposure to        litigation and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50065498&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=67856ee9cd25179fd853464002a9d3f4\">www.sec.gov<\/a>).     <\/p>\n<p class=\"bwalignc\">\n<p><p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Investor:<br \/>Alex        Kelly, 908-423-5185     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known outside the United States and Canada as MSD, today is hosting a R&amp;D and Business Briefing. &#8220;Innovation is the centerpiece of our growth strategy at Merck,&#8221; said Kenneth C. Frazier, president and chief executive officer. &#8220;We continue to make significant progress on our strategy to drive growth from our existing portfolio and to bring forward breakthrough medicines and vaccines that address unmet medical needs and return significant value to our shareholders.&#8221; At the meeting, Peter S. Kim, president of Merck Research Laboratories, four of the company&#8217;s therapeutic area research franchise heads, and the president of Merck BioVentures provided an overview of candidates in development and progress in advancing the company&#8217;s pipeline. Merck has 19 candidates in Phase III clinical trials targeting a broad range of diseases. The company plans to submit eight new U.S. filings in 2012-2013, including five new candidates: TREDAPTIVE [ER niacin\/laropiprant]<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742068","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known outside the United States and Canada as MSD, today is hosting a R&amp;D and Business Briefing. &quot;Innovation is the centerpiece of our growth strategy at Merck,&quot; said Kenneth C. Frazier, president and chief executive officer. &quot;We continue to make significant progress on our strategy to drive growth from our existing portfolio and to bring forward breakthrough medicines and vaccines that address unmet medical needs and return significant value to our shareholders.&quot; At the meeting, Peter S. Kim, president of Merck Research Laboratories, four of the company&#039;s therapeutic area research franchise heads, and the president of Merck BioVentures provided an overview of candidates in development and progress in advancing the company&#039;s pipeline. Merck has 19 candidates in Phase III clinical trials targeting a broad range of diseases. The company plans to submit eight new U.S. filings in 2012-2013, including five new candidates: TREDAPTIVE [ER niacin\/laropiprant]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\\\/\",\"name\":\"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-11-10T09:55:00+00:00\",\"dateModified\":\"2026-08-10T17:01:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&#038;D and Business Briefing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/","og_locale":"en_US","og_type":"article","og_title":"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing - Merck.com","og_description":"Merck (NYSE:MRK), known outside the United States and Canada as MSD, today is hosting a R&amp;D and Business Briefing. \"Innovation is the centerpiece of our growth strategy at Merck,\" said Kenneth C. Frazier, president and chief executive officer. \"We continue to make significant progress on our strategy to drive growth from our existing portfolio and to bring forward breakthrough medicines and vaccines that address unmet medical needs and return significant value to our shareholders.\" At the meeting, Peter S. Kim, president of Merck Research Laboratories, four of the company's therapeutic area research franchise heads, and the president of Merck BioVentures provided an overview of candidates in development and progress in advancing the company's pipeline. Merck has 19 candidates in Phase III clinical trials targeting a broad range of diseases. The company plans to submit eight new U.S. filings in 2012-2013, including five new candidates: TREDAPTIVE [ER niacin\/laropiprant]","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:15+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/","name":"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&amp;D and Business Briefing - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-11-10T09:55:00+00:00","dateModified":"2026-08-10T17:01:15+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-pipeline-progress-and-showcases-novel-innovations-at-rd-and-business-briefing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&#038;D and Business Briefing"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9fa49381-a4b9-4b6e-a487-f50fa138686c","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Highlights-Pipeline-Progress-and-Showcases-Novel-Innovations-at-RD-and-Business-Briefing-2011.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742068\/revisions"}],"predecessor-version":[{"id":3679204,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742068\/revisions\/3679204"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742068"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}